[Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology]. / Moderne Therapie der chronischen [corrected] myeloischen Leukämie : Ein Beispiel für den Paradigmenwechsel in der Hämatoonkologie.
Internist (Berl)
; 52(2): 209-17, 2011 Feb.
Article
em De
| MEDLINE
| ID: mdl-21225238
ABSTRACT
Chronic myeloid leukemia (CML) is exceptional amongst neoplasias since its underlying pathomechanism has been elucidated, and potent well tolerated targeted drugs, the tyrosine kinase inhibitors (TKI), are available for treatment. They convincingly improve prognosis while retaining good quality of life. Aims of therapy are complete remissions as well as prolongation of life and cure. Imatinib 400 mg per day is current standard therapy. There are hints for a better outcome with a higher initial imatinib dose or with combination therapy. Even after achievement of complete molecular response continuous therapy might be necessary in most cases. In case of imatinib intolerance or failure, the second generation TKI dasatinib and nilotinib and allogeneic stem cell transplantation are available. The use of second generation TKI as first line treatment might further improve prognosis. The therapeutic response should be regularly monitored according to international recommendations.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Proteínas Tirosina Quinases
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Transplante de Células-Tronco
/
Inibidores de Proteínas Quinases
/
Antineoplásicos
Tipo de estudo:
Guideline
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
De
Revista:
Internist (Berl)
Ano de publicação:
2011
Tipo de documento:
Article